Article ID: MS7112011
Summary: Enhanced oncogenic Y-box binding protein-1 (YB-1) expression, associated with the aberrant expression of genes involved in cell proliferation, survival, and drug resistance, can predict prognostic outcomes in patients with various malignancies. We examined whether YB-1 could predict prognostic outcomes in patients with endometrial cancer and whether enhanced YB-1 expression affects the expression of mammalian target of rapamycin (mTOR) in endometrial cancer. We examined the expression levels of YB-1 and mTOR in tumor samples of 166 patients with endometrial cancer, including those with endometrioid grade 1–3, serous carcinoma, and stage I–IV disease, who underwent surgery. The expression levels of both molecules were assessed using immunohistochemical analysis. The correlation between the expression levels of YB-1 or mTOR and prognosis was also confirmed.
The positivity rate of nuclear YB-1 expression was 9.4%. YB-1 expression was associated with poor progression-free survival (P = 0.012) and overall survival (P = 0.003). Fifty-nine patients (35.5%) exhibited mTOR expression. Nuclear YB-1 expression was also correlated with mTOR expression (P = 0.006). We observed similar results when examining only patients who underwent adjuvant chemotherapy. Enhanced nuclear YB-1 expression could predict poor outcomes in endometrial cancer and was significantly associated with enhanced mTOR expression.
